William R Wilson Selected Research

Oxides

7/2019	Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors.
1/2017	Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice.
10/2014	Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5.
12/2013	Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
3/2012	The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
3/2012	Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
1/2004	Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
9/2003	Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William R Wilson Research Topics

Disease

75	Hypoxia (Hypoxemia) 01/2022 - 12/2002
56	Neoplasms (Cancer) 06/2022 - 03/2002
4	Squamous Cell Carcinoma of Head and Neck 01/2022 - 01/2018
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2015 - 01/2011
4	Leukemia 09/2015 - 01/2011
3	Body Weight (Weight, Body) 01/2022 - 01/2003
3	Carcinoma (Carcinomatosis) 02/2005 - 01/2004
2	Breast Neoplasms (Breast Cancer) 06/2022 - 10/2020
2	Hypersensitivity (Allergy) 10/2020 - 06/2009
2	Infections 01/2019 - 10/2011
2	Hypothermia 01/2019 - 01/2017
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 09/2015 - 03/2014
2	Hepatocellular Carcinoma (Hepatoma) 01/2015 - 08/2011
2	Thrombocytopenia (Thrombopenia) 10/2011 - 08/2011
1	Rupture 06/2022
1	Thrombosis (Thrombus) 02/2021
1	Acidosis 07/2019
1	Necrosis 10/2018

Drug/Important Bio-Agent (IBA)

61	ProdrugsIBA 10/2021 - 03/2002
22	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2004
22	Oxidoreductases (Dehydrogenase)IBA 10/2020 - 09/2007
21	PR-104AIBA 01/2018 - 07/2007
20	Tirapazamine (SR 4233)IBA 01/2017 - 01/2003
20	PR-104IBA 09/2015 - 07/2007
17	Pharmaceutical PreparationsIBA 06/2022 - 01/2003
16	Oxygen (Dioxygen)IBA 12/2021 - 06/2004
15	Cytotoxins (Cytolysins)IBA 05/2016 - 01/2004
14	CEN-209IBA 01/2019 - 10/2010
9	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2009
9	Phosphates (Orthophosphate)IBA 01/2018 - 09/2007
9	Alkylating AgentsIBA 07/2013 - 09/2004
8	OxidesIBA 07/2019 - 09/2003
8	TH 302IBA 01/2019 - 12/2013
7	Mechlorethamine (Nitrogen Mustard)FDA Link 01/2018 - 04/2003
7	Aldo-Keto ReductasesIBA 01/2017 - 03/2010
7	EstersIBA 09/2015 - 09/2007
5	NADPH-Ferrihemoprotein Reductase (Cytochrome P450 Reductase)IBA 10/2020 - 06/2007
5	Hydroxylamine (Hydroxylamine Hydrochloride)IBA 10/2018 - 07/2007
5	AminesIBA 01/2015 - 12/2002
4	Liposomes (Liposome)IBA 06/2022 - 01/2010
4	Messenger RNA (mRNA)IBA 01/2019 - 06/2011
4	Antineoplastic Agents (Antineoplastics)IBA 01/2017 - 10/2002
3	green 5IBA 01/2019 - 01/2013
3	azomycinIBA 01/2018 - 08/2013
3	EnzymesIBA 10/2015 - 03/2002
3	Cisplatin (Platino)FDA LinkGeneric 11/2014 - 01/2004
3	SolutionsIBA 11/2014 - 06/2004
3	NitrogenIBA 11/2014 - 11/2008
3	Nitro CompoundsIBA 12/2013 - 10/2009
3	cyclenIBA 07/2013 - 09/2004
3	CobaltIBA 07/2013 - 06/2006
3	LigandsIBA 07/2013 - 09/2004
3	tretazicarIBA 06/2004 - 03/2002
2	AcidsIBA 06/2022 - 07/2019
2	IC87361IBA 12/2019 - 11/2019
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 11/2019 - 01/2018
2	Small Interfering RNA (siRNA)IBA 01/2019 - 05/2012
2	Gemcitabine FDA Link 01/2019 - 07/2007
2	pimonidazoleIBA 01/2019 - 07/2015
2	Glucose (Dextrose)FDA LinkGeneric 10/2018 - 01/2013
2	4-nitroimidazoleIBA 01/2018 - 04/2014
2	NitroimidazolesIBA 01/2018 - 04/2014
2	TriazinesIBA 01/2017 - 11/2008
2	Carbonic Anhydrase IXIBA 07/2015 - 01/2012
2	Sorafenib (BAY 43-9006)FDA Link 01/2015 - 08/2011
2	Proteins (Proteins, Gene)FDA Link 10/2014 - 05/2012
2	Zinc Finger NucleasesIBA 12/2013 - 01/2013
2	Adenosine Diphosphate (ADP)IBA 01/2013 - 05/2012
2	Adenine FDA LinkGeneric 01/2012 - 10/2009
2	SaltsIBA 01/2012 - 12/2002
2	DuocarmycinsIBA 08/2011 - 03/2011
2	nitromide (Unistat)IBA 03/2010 - 07/2007
2	3-amino-1,2,4-benzotriazine-1-oxideIBA 06/2004 - 01/2004
1	CalciumIBA 06/2022
1	Protons (Proton)IBA 06/2022
1	AZD7648IBA 01/2022
1	CopperIBA 10/2020
1	Hydroxyl RadicalIBA 10/2020
1	olaparibIBA 12/2019
1	veliparibIBA 12/2019
1	8- dibenzothiophen- 4- yl- 2- morpholin- 4- yl- chromen- 4- oneIBA 12/2019
1	DNA-Activated Protein KinaseIBA 11/2019
1	formic acid (formate)IBA 11/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2019
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 04/2019
1	meropenem and vaborbactamIBA 01/2019
1	isophosphamide mustard (IPAM)IBA 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	imidazoleIBA 10/2018
1	DNA AdductsIBA 01/2018
1	Free RadicalsIBA 01/2018

Therapy/Procedure

15	Radiotherapy 12/2021 - 01/2004
15	Therapeutics 07/2019 - 03/2002
8	Drug Therapy (Chemotherapy) 04/2019 - 01/2003
4	Aftercare (After-Treatment) 08/2013 - 08/2006
1	Immunotherapy 01/2022
1	Critical Care (Surgical Intensive Care) 02/2021
1	Precision Medicine 01/2019
1	Chemoradiotherapy 01/2019